Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for advanced progressive adrenocortical carcinoma (Phase 2, open-label)
2022-000494-91Phase 2Active
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- May 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in adrenal cancer (ACC), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: Tumor response to pembrolizumab. Started May 2022; status: active.
02
Drugs
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2022-000494-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000494-91.